195 related articles for article (PubMed ID: 31987971)
1. Clinical Significance of Vulnerability Assessment in Patients with Primary Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiation Therapy.
Chou WC; Chang PH; Chen PT; Wang HM; Yeh KY; Lu CH; Hung YS; Tung-Chieh Chang J; Tsang NM; Ho YW; Chen SY; Lee SH; Hung CY; Wang LJ; Liao KC; Lin CH; Tang WR; Lin YC
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(3):602-611. PubMed ID: 31987971
[TBL] [Abstract][Full Text] [Related]
2. Clinical Significance of Frailty on Treatment Outcome in Nongeriatric Patients With Head and Neck Cancer and Esophageal Cancer Undergoing Curative-Intent Concurrent Chemoradiotherapy.
Chou WC; Lai CC; Hung CY; Hsueh SW; Yeh KY; Lu CH; Tsang NM; Chang PH; Ho YW; Chen SY; Lin YC; Hung YS
Cancer Control; 2022; 29():10732748211045276. PubMed ID: 34994207
[TBL] [Abstract][Full Text] [Related]
3. A comparison of the MNA-SF, MUST, and NRS-2002 nutritional tools in predicting treatment incompletion of concurrent chemoradiotherapy in patients with head and neck cancer.
Hsueh SW; Lai CC; Hung CY; Lin YC; Lu CH; Yeh KY; Tsang NM; Hung YS; Chang PH; Chou WC
Support Care Cancer; 2021 Sep; 29(9):5455-5462. PubMed ID: 33704566
[TBL] [Abstract][Full Text] [Related]
4. A prospective nutritional assessment using Mini Nutritional Assessment-short form among patients with head and neck cancer receiving concurrent chemoradiotherapy.
Hung CY; Hsueh SW; Lu CH; Chang PH; Chen PT; Yeh KY; Wang HM; Tsang NM; Huang PW; Hung YS; Chen SC; Chou WC
Support Care Cancer; 2021 Mar; 29(3):1509-1518. PubMed ID: 32710174
[TBL] [Abstract][Full Text] [Related]
5. Potential Utility of the Mallampati Score for Prediction of Treatment Compliance and Safety Profiles of Patients With Head and Neck Cancer Undergoing Definitive Concurrent Chemoradiotherapy.
Su PH; Hsu CC; Hsueh SW; Hung CY; Yeh KY; Wang HM; Lu CH; Lin YC; Chang JT; Chou WC
Anticancer Res; 2022 Nov; 42(11):5609-5618. PubMed ID: 36288852
[TBL] [Abstract][Full Text] [Related]
6. The Geriatric Nutritional Risk Index as a prognostic factor in older adult patients with locally advanced head and neck cancer receiving definitive chemoradiotherapy with tri-weekly cisplatin.
Fujiwara Y; Sato Y; Hayashi N; Fukuda N; Wang X; Nakano K; Ohmoto A; Urasaki T; Ono M; Tomomatsu J; Toshiyasu T; Mitani H; Takahashi S
J Geriatr Oncol; 2023 Jun; 14(5):101523. PubMed ID: 37229881
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of the pretreatment geriatric nutritional risk index for predicting severe adverse events in patients with head and neck cancer treated with chemoradiotherapy.
Nakayama M; Ohnishi K; Adachi M; Ii R; Matsumoto S; Nakamura M; Miyamoto H; Hirose Y; Nishimura B; Tanaka S; Wada T; Tabuchi K
Auris Nasus Larynx; 2022 Apr; 49(2):279-285. PubMed ID: 34509306
[TBL] [Abstract][Full Text] [Related]
8. Frailty is an independent factor for health-related quality of life in patients with head and neck cancer receiving definitive concurrent chemoradiotherapy.
Lu CH; Hung CY; Hsueh SW; Yeh KY; Hung YS; Chou WC
Support Care Cancer; 2024 Jan; 32(2):106. PubMed ID: 38221588
[TBL] [Abstract][Full Text] [Related]
9. Impact of Frailty on Treatment Outcome in Patients With Locally Advanced Esophageal Cancer Undergoing Concurrent Chemoradiotherapy.
Huang YH; Hung YS; Lai CC; Ho MM; Yeh KY; Yang C; Lu CH; Tseng CK; Tsang NM; Hung CY; Hsueh SW; Chang PH; Ho YW; Lin YC; Chou WC
Anticancer Res; 2021 Oct; 41(10):5213-5222. PubMed ID: 34593474
[TBL] [Abstract][Full Text] [Related]
10. Weekly Low-Dose Versus Three-Weekly High-Dose Cisplatin for Concurrent Chemoradiation in Locoregionally Advanced Non-Nasopharyngeal Head and Neck Cancer: A Systematic Review and Meta-Analysis of Aggregate Data.
Szturz P; Wouters K; Kiyota N; Tahara M; Prabhash K; Noronha V; Castro A; Licitra L; Adelstein D; Vermorken JB
Oncologist; 2017 Sep; 22(9):1056-1066. PubMed ID: 28533474
[TBL] [Abstract][Full Text] [Related]
11. Benefits of immunonutrition in patients with head and neck cancer receiving chemoradiation: A phase II randomized, double-blind study.
Dechaphunkul T; Arundon T; Raungkhajon P; Jiratrachu R; Geater SL; Dechaphunkul A
Clin Nutr; 2022 Feb; 41(2):433-440. PubMed ID: 35007812
[TBL] [Abstract][Full Text] [Related]
12. Feasibility and toxicity of concurrent chemoradiation for elderly patients with head and neck cancer.
Daly ME; Lau DH; Farwell DG; Luu Q; Donald PJ; Chen AM
Am J Otolaryngol; 2013; 34(6):631-5. PubMed ID: 23954137
[TBL] [Abstract][Full Text] [Related]
13. Artificial nutrition dependence after cetuximab versus cisplatin combined with radiotherapy for advanced head and neck cancer: A propensity score-matched analysis.
Ishimaru M; Ono S; Suzuki S; Matsui H; Fushimi K; Yasunaga H
Head Neck; 2017 Feb; 39(2):320-325. PubMed ID: 27635865
[TBL] [Abstract][Full Text] [Related]
14. Effect of prophylactic tube feeding in head and neck cancer patients with high Mallampati score undergoing definitive concurrent chemoradiotherapy.
Lu CH; Hsu CC; Su PH; Lin SY; Yeh KY; Hsueh SW; Chang JT; Wang HM; Hung YS; Chou WC
Support Care Cancer; 2023 Jun; 31(7):384. PubMed ID: 37289404
[TBL] [Abstract][Full Text] [Related]
15. Impact of concomitant chemoradiation on survival for patients with T1-2N1 head and neck cancer.
Zumsteg ZS; Kim S; David JM; Yoshida EJ; Tighiouart M; Shiao SL; Scher K; Mita A; Sherman EJ; Lee NY; Ho AS
Cancer; 2017 May; 123(9):1555-1565. PubMed ID: 28001302
[TBL] [Abstract][Full Text] [Related]
16. Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy.
VanderWalde NA; Deal AM; Comitz E; Stravers L; Muss H; Reeve BB; Basch E; Tepper J; Chera B
Int J Radiat Oncol Biol Phys; 2017 Jul; 98(4):850-857. PubMed ID: 28258889
[TBL] [Abstract][Full Text] [Related]
17. Frailty as a predictor of outcomes in patients undergoing head and neck cancer surgery.
Goldstein DP; Sklar MC; de Almeida JR; Gilbert R; Gullane P; Irish J; Brown D; Higgins K; Enepekides D; Xu W; Su J; Alibhai SMH
Laryngoscope; 2020 May; 130(5):E340-E345. PubMed ID: 31418866
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-analysis of Conventionally Fractionated Concurrent Chemoradiotherapy versus Altered Fractionation Radiotherapy Alone in the Definitive Management of Locoregionally Advanced Head and Neck Squamous Cell Carcinoma.
Gupta T; Kannan S; Ghosh-Laskar S; Agarwal JP
Clin Oncol (R Coll Radiol); 2016 Jan; 28(1):50-61. PubMed ID: 26454839
[TBL] [Abstract][Full Text] [Related]
19. Impact of the pretreatment Glasgow prognostic score on treatment tolerance, toxicities, and survival in patients with advanced head and neck cancer undergoing concurrent chemoradiotherapy.
Chang PH; Yeh KY; Wang CH; Chen EY; Yang SW; Huang JS; Chou WC; Hsieh JC
Head Neck; 2017 Oct; 39(10):1990-1996. PubMed ID: 28688124
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of Induction Chemotherapy for Head and Neck Cancer Patients: A Combined Study of Two National Cohorts in Taiwan.
Chen JH; Yen YC; Liu SH; Yuan SP; Wu LL; Lee FP; Lin KC; Lai MT; Wu CC; Chen TM; Chang CL; Chow JM; Ding YF; Lin MC; Wu SY
Medicine (Baltimore); 2016 Feb; 95(7):e2845. PubMed ID: 26886647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
